TBPH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TBPH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Theravance Biopharma's interest expense for the three months ended in Dec. 2023 was $ -0.62 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.35 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Theravance Biopharma's Operating Income for the three months ended in Dec. 2023 was $ -6.60 Mil. Theravance Biopharma's Interest Expense for the three months ended in Dec. 2023 was $ -0.62 Mil. Theravance Biopharma did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
The historical data trend for Theravance Biopharma's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theravance Biopharma Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Interest Expense | Get a 7-Day Free Trial | -31.86 | -8.55 | -8.55 | -6.37 | -2.35 |
Theravance Biopharma Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Interest Expense | Get a 7-Day Free Trial | -0.55 | -0.55 | -0.57 | -0.61 | -0.62 |
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.35 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theravance Biopharma (NAS:TBPH) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Theravance Biopharma's Interest Expense for the three months ended in Dec. 2023 was $-0.62 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-6.60 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $45.24 Mil.
Theravance Biopharma's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
Theravance Biopharma did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Rhonda Farnum | officer: SVP, Comm & Medical Affairs | 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080 |
Richard A Graham | officer: SVP, Development | 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080 |
Kelly James Connor | director | 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080 |
Susannah Gray | director | 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121 |
Brett A. Grimaud | officer: SVP, Gen Counsel and Secretary | 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080 |
Aziz Sawaf | officer: SVP & Chief Financial Officer | 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080 |
Rick E Winningham | director, officer: Chief Executive Officer | 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Andrew A. Hindman | officer: SVP, Chief Financial Officer | C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Eli Samaha | 10 percent owner | ONE WORLD TRADE CENTER, FLOOR 65, NEW YORK NY 10007 |
Wam Gp Llc | 10 percent owner | 222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116 |
Andrew M Weiss | 10 percent owner | 222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116 |
Weiss Asset Management Lp | 10 percent owner | 222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116 |
Philip D Worboys | officer: SVP, Translational Science | 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080 |
Brett K Haumann | officer: VP-Clinical Develop. | 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080 |
Deepika Pakianathan | director | 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402 |
From GuruFocus
By PRNewswire • 11-14-2023
By PRNewswire PRNewswire • 04-24-2023
By PRNewswire PRNewswire • 05-09-2023
By PRNewswire PRNewswire • 04-11-2023
By PRNewswire PRNewswire • 07-05-2022
By Business Wire Business Wire • 02-27-2023
By PRNewswire • 11-16-2023
By PRNewswire PRNewswire • 07-26-2022
By PRNewswire • 12-21-2023
By PRNewswire • 10-19-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.